Journey Medical (DERM) Return on Capital Employed (2021 - 2026)

Journey Medical's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 11.48% for Q1 2026.

• Quarterly Return on Capital Employed rose 483.0% year-over-year to 11.48% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.48% (up 483.0% YoY) and the FY2025 annual result came in at 16.35%, up 1518.0% from the prior year.
• Return on Capital Employed was 11.48% for Q1 2026 at Journey Medical, up from 15.58% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 6.69% in Q2 2024 and bottomed at 251.26% in Q2 2023.
• A 5-year average of 51.82% and a median of 37.0% in 2024 frame the typical range for Return on Capital Employed.
• Annual changes were most pronounced in 2023 — Return on Capital Employed plunged 19918 bps — and 2024, when it jumped 25795 bps.
• Journey Medical's Return on Capital Employed stood at 69.1% in 2022, then jumped by 90 bps to 7.02% in 2023, then plunged by 427 bps to 37.0% in 2024, then soared by 58 bps to 15.58% in 2025, then gained by 26 bps to 11.48% in 2026.
• Business Quant data shows DERM's Return on Capital Employed at 11.48% in Q1 2026, 15.58% in Q4 2025, and 12.64% in Q3 2025.